Sharps TechnologySTSS
STSS
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
616% more capital invested
Capital invested by funds: $93.4K [Q3] → $668K (+$575K) [Q4]
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
10.23% more ownership
Funds ownership: 2.18% [Q3] → 12.41% (+10.23%) [Q4]
40% less funds holding
Funds holding: 10 [Q3] → 6 (-4) [Q4]
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Research analyst outlook
We haven’t received any recent analyst ratings for STSS.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on March 28, 2025
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: STSS) (the “Company” or “Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company's proposal before the shareholder meeting, which is scheduled to be held on March 28, 2025, at 10:00 a.m. Eastern Time.
Neutral
GlobeNewsWire
1 month ago
Sharps Technology's CEO Issues Corporate Update Highlighting Agreements for SecureGard and SoloGard and Revenue Developments from Manufacturing Operations in Hungary
Company is strategically positioned following the recent $20 million capital raise, enhancing manufacturing capabilities to accelerate qualification and shipments under existing agreements Company is strategically positioned following the recent $20 million capital raise, enhancing manufacturing capabilities to accelerate qualification and shipments under existing agreements
Neutral
GlobeNewsWire
2 months ago
Sharps Technology, Inc. Announces Closing of Upsized $20.0 Million Underwritten Public Offering
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The offering closed on January 29, 2025.
Neutral
GlobeNewsWire
4 months ago
Sharps Technology's CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and SoloGard Product Supply and Revenue
NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, issues a shareholder letter from Robert Hayes, the Company's Chief Executive Officer.
Neutral
GlobeNewsWire
4 months ago
Sharps Regains Nasdaq Listing Compliance
NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that on November 13, 2024, the Company was notified by the Nasdaq Stock Market (“Nasdaq”) that the Company had regained compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Stock Market, as set forth in Nasdaq Listing Rule 5550(a)(2) as of November 5, 2024.
Neutral
GlobeNewsWire
5 months ago
Sharps Technology, Inc. Announces Stockholders' Approval of Reverse Stock Split Ratio and Effective Date
NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) ("Sharps"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it will effect a one-for-22 reverse stock split (the "reverse split") of its common stock, par value $0.0001 per share (the "Common Stock"), that will become effective on October 15, 2024 at 11:59 PM Eastern Time, before the opening of trading on The Nasdaq Capital Market ("Nasdaq"). Sharps has requested that its Common Stock begin trading on October 16, 2024, on a post-reverse split basis on the Nasdaq under the existing symbol "STSS".
Neutral
GlobeNewsWire
6 months ago
Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on October 7, 2024
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the Company's proposal before the shareholder meeting scheduled to be held on October 7, 2024 at 10:00 a.m. Eastern Time.
Neutral
Accesswire
6 months ago
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS)
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.5 Million Bridge Financing for Sharps Technology, Inc. (NASDAQ:STSS). About Sharps Technology, Inc. Sharps Technology, Inc., a medical device company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States.
Neutral
GlobeNewsWire
6 months ago
Sharps Technology, Inc. Closes $3.5 Million Bridge Financing
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million.
Neutral
GlobeNewsWire
6 months ago
Sharps Technology, Inc. Announces $3.5 Million Bridge Financing
NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into definitive agreements with institutional investors for a secured bridge loan financing (the “Bridge Financing”) of approximately $3.5 million.
Charts implemented using Lightweight Charts™